Form 4: Community Health Systems SVP & CAO Jason K. Johnson Reports Stock Transactions

Jason K. Johnson, SVP & CAO of Community Health Systems, reports the vesting and forfeiture of performance-based restricted shares, acquisition of restricted stock, and stock option grants.

Summary

• On March 1, 2025, Jason K. Johnson, SVP & CAO of Community Health Systems, filed a Form 4 detailing changes in beneficial ownership.
• 5,250 performance-based restricted shares vested based on the achievement of certain performance objectives between 2022 and 2024, while 19,750 shares were forfeited due to not meeting the performance objectives.
• Johnson acquired 30,000 shares of restricted stock, which will vest in equal increments over three years.
• He also acquired 30,000 performance-based restricted shares tied to performance objectives between 2025 and 2027.
• These objectives are split equally between Cumulative Same-Store Adjusted EBITDA Growth and Cumulative Same-Store Net Revenue Growth.
• Additionally, Johnson acquired 30,000 stock options with an exercise price of $2.87, vesting in equal increments over three years and expiring on February 28, 2034.
• The reporting person directly owns 172,049 shares of common stock after the reported transactions.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While there's a forfeiture of shares due to missed targets, there's also the granting of new stock and options, suggesting continued investment in the executive. It's a mixed bag, leaning slightly positive due to the ongoing incentives.

Positives

• The acquisition of 30,000 shares of restricted stock indicates confidence in the company's future performance.
• The grant of 30,000 performance-based restricted shares incentivizes management to achieve specific financial targets (EBITDA and revenue growth).

Negatives

• The forfeiture of 19,750 performance-based restricted shares suggests that the company did not fully achieve its performance objectives for the 2022-2024 period.
• The vesting of only 21% of the target number of performance-based restricted shares indicates underperformance against the set goals.

Risks

• Failure to meet the performance objectives for the 2025-2027 period could result in the forfeiture of a significant portion of the newly granted performance-based restricted shares.
• Fluctuations in the company's stock price could impact the value of the stock options and restricted stock held by the reporting person.

Future Outlook

The vesting of future performance-based restricted shares is contingent upon the achievement of pre-determined performance objectives related to EBITDA and revenue growth between 2025 and 2027.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with those of shareholders. The vesting and granting of stock options and restricted stock are common practices in the healthcare industry to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Executive compensation packages in the healthcare industry often include a mix of base salary, cash bonuses, stock options, and restricted stock units (RSUs).
• Companies like HCA Healthcare and Universal Health Services also utilize performance-based equity awards tied to metrics such as revenue growth, profitability, and patient satisfaction.
• The specific performance metrics and vesting schedules vary depending on the company's strategic priorities and compensation philosophy.
• The use of same-store metrics is common in the healthcare industry to assess the performance of existing facilities and operations.

Stakeholder Impact

• Shareholders may be interested in the performance metrics tied to the vesting of performance-based restricted shares, as they align management's interests with the company's financial performance.
• Employees may view the executive compensation package as an indicator of the company's commitment to attracting and retaining talent.

Next Steps

• Monitor the company's performance against the EBITDA and revenue growth targets for the 2025-2027 period to assess the potential vesting of the performance-based restricted shares.
• Track the company's stock price to evaluate the value of the stock options and restricted stock held by the reporting person.

Key Dates